Interleukin 17 role as a biomarker in Systemic Lupus Erythematosus patients.

Document Type : Original Article

Authors

1 Assistant Lecturer of Clinical and Chemical Pathology-Faculty of medicine- Sohag University.

2 Lecturer of Clinical and Chemical Pathology-Faculty of medicine-Sohag University.

3 Assistant Professor of Clinical and Chemical Pathology-Faculty of medicine-Sohag University.

4 Associate Professor of Clinical hematology and bone marrow transplant -Internal medicine department -faculty of medicine-Assiut University.

5 Assistant Professor of Clinical hematology and bone marrow transplant -Internal medicine department -Faculty of medicine-Assiut University.

6 Professor of Clinical Pathology-South Egypt Cancer Institute-Assiut University.

Abstract

Abstract:

Objective: The purpose of this study is to determine the interleukin 17 (IL-17) level in cases with Systemic lupus erythematosus (SLE), in addition to assessing the correlation of IL-17 with the activity of the disease. Patients and Methods: The present research recruited 60 adult SLE cases versus 60 healthy subjects serving as controls. Subjects had a full clinical evaluation, history taking as well as evaluation of disease activity in cases with SLE via the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). The serum level of IL-17 was measured in controls as well as SLE patients. Results: The IL-17 levels were substantially elevated in the SLE cohort than in controls. In addition, its level was positively related to SLEDAI. Conclusion: The present study findings revealed maximized IL-17 levels in SLE cases, denoting their contribution to the activity as well as the pathogenesis of the disease. Serum IL-17 levels were significantly positively related to the activity of the disease, 24 h protein in the urine, and anti-dsDNA.

Keywords

Main Subjects

Files

Share

How to cite

Statistics